Earnings Releases·Nov 12, 2026, 5:11 PM ET

Longeveron Inc. — Third Quarter 2026 Earnings Summary

Total revenue decreased 16% to $0.1 million year-over-year, driven by the absence of $43,000 in contract manufacturing revenue, while net loss narrowed 15% to $6.1 million from $7.2 million in 2025, aided by a $1.0 million XPRIZE milestone award.
The ELPIS II Phase 2b trial for HLHS missed its primary efficacy endpoint, prompting an FDA meeting to determine next steps, though the drug showed statistical significance in reducing major adverse cardiac events compared to standard of care.
Cash and cash equivalents increased to $7.2 million as of September 30, 2026, sufficient to fund operations into Q1 2027, while the company evaluates strategic alternatives including partnerships, financing, or a business combination.
Regulatory progress includes the effective IND for Pediatric Dilated Cardiomyopathy (PDCM) enabling a Phase 2 trial, and FDA RMAT/Fast Track designations for laromestrocel in Alzheimer's disease.
Key corporate developments include the appointment of a new CFO, the election of a new board member, the retention of Lucid Capital Markets as a financial advisor, and the effectiveness of a 1-for-10 reverse stock split.